ALLFEN DM
-
guaifenesin and
dextromethorphan hydrobromide tablet
MCR American Pharmaceuticals, Inc.
Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.
----------
temporarily relieves
Do not use this product unless directed by a doctor
Do not exceed recommended dosage.
Adults and children 12 years of age and over: | 1 tablet every 4 hours, not to exceed 6 tablets in 24 hours, or as directed by a doctor |
Children 6 to under 12 years of age: | 1/2 tablet every 4 hours, not to exceed 3 tablets in 24 hours, or as directed by a doctor |
Children 2 to under 6 years of age: | Consult a doctor |
NDC 58605-0401-01
100 tablets
Allfen DM
Antitussive • Expectorant
Each immediate-release tablet contains: | |
Dextromethorphan HBr | 20 mg |
Guaifenesin | 400 mg |
MCR American
ALLFEN DM
guaifenesin and dextromethorphan hydrobromide tablet |
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
||||||||||||||||||
|
Marketing Information | |||
Marketing Category | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
OTC MONOGRAPH FINAL | part341 | 03/31/2008 |
Labeler - MCR American Pharmaceuticals, Inc. (783383011) |
Establishment | |||
Name | Address | ID/FEI | Operations |
MCR American Pharmaceuticals, Inc. | 783383011 | MANUFACTURE |
Revised: 05/2011 MCR American Pharmaceuticals, Inc.